Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-negative,ER-positive) and gBRCA or HDR-positive Metastatic Breast Cancer(LUZERN)

Conditions:   Breast Cancer;   Breast Cancer Metastatic Intervention:   Drug: Niraparib 100 MG Sponsors:   MedSIR;   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials